| Vascular endothelial growth factor (VEGF) inhibition--a critical review. | |
| | |
MedLine Citation:
|
PMID: 17348829 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Angiogenesis, or formation of new blood capillaries from preexisting vessels, plays both beneficial and damaging roles in the organism. It is a result of a complex balance of positive and negative regulators, and vascular endothelial growth factor (VEGF) is one of the most important pro-angiogenic factors involved in tumor angiogenesis. VEGF increases vascular permeability, which might facilitate tumor dissemination via the circulation causing a greater delivery of oxygen and nutrients; it recruits circulating endothelial precursor cells, and acts as a survival factor for immature tumor blood vessels. The endotheliotropic activities of VEGF are mediated through the VEGF-specific tyrosine-kinase receptors: VEGFR-1, VEGFR-2 and VEGFR-3. VEGF and its receptors play a central role in tumor angiogenesis, and therefore the blockade of this pathway is a promising therapeutic strategy for inhibiting angiogenesis and tumor growth. A number of different strategies to inhibit VEGF signal transduction are in development and they include the development of humanized neutralizing anti-VEGF monoclonal antibodies, receptor antagonists, soluble receptors, antagonistic VEGF mutants, and inhibitors of VEGF receptor function. These agents can be divided in two broad classes, namely agents designed to target the VEGF activity and agents designed to target the surface receptor function. The main purpose of this review is to summarize all the available information regarding the importance of the pro-angiogenic factor VEGF in cancer therapy. After an overview of the VEGF family and their respective receptors, we shall focus our attention on the different VEGF-inhibitors existent nowadays. Agents based upon anti-VEGF therapy have provided solid proofs about their success, and therefore we believe that a critical review is of the utmost importance to help researchers in their future work. |
| | |
Authors:
|
Irina Sousa Moreira; Pedro Alexandrino Fernandes; Maria João Ramos |
Related Documents
:
|
22613709 - Adrenergic regulation of hcn4 channel requires protein association with β2-adrenergic ... 16413169 - Receptor-type ptp-np inhibition of dynamin-1 gtpase activity is associated with neurona... 10942749 - Overexpression of g protein-coupled receptor kinase-2 in smooth muscle cells attenuates... 18487369 - Vascular endothelial growth factor mediates corneal nerve repair. 16505489 - Vascular endothelial growth factor (vegf)/vegf-c mosaic molecules reveal specificity de... 18632559 - Soluble receptor-mediated selective inhibition of vegfr and pdgfrbeta signaling during ... 15037219 - Buprenorphine produces naltrexone reversible alterations of immune status. 20673729 - Discovery of 2-(4-((1h-1,2,4-triazol-1-yl)methyl)-5-(4-bromophenyl)-1-(2-chlorophenyl)-... 10581199 - Rapid nongenomic effects of aldosterone in mineralocorticoid-receptor-knockout mice. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Anti-cancer agents in medicinal chemistry Volume: 7 ISSN: 1871-5206 ISO Abbreviation: - Publication Date: 2007 Mar |
Date Detail:
|
Created Date: 2007-03-12 Completed Date: 2007-04-02 Revised Date: 2009-11-19 |
Medline Journal Info:
|
Nlm Unique ID: 101265649 Medline TA: Anticancer Agents Med Chem Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 223-45 Citation Subset: IM |
Affiliation:
|
REQUIMTE/Departamento de Química, Faculdade de Ciências da Universidade do Porto, Rua do Campo Alegre 687, 4169-007 Porto, Portugal. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Angiogenesis Inhibitors
/
chemical synthesis,
pharmacology* Animals Humans Models, Molecular Neovascularization, Pathologic / drug therapy, pathology Receptors, Vascular Endothelial Growth Factor / drug effects Vascular Endothelial Growth Factor A / antagonists & inhibitors*, physiology |
| Chemical | |
Reg. No./Substance:
|
0/Angiogenesis Inhibitors; 0/Vascular Endothelial Growth Factor A; EC 2.7.10.1/Receptors, Vascular Endothelial Growth Factor |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Meta-analysis of anticancer drug structures--significance of their polar allylic moieties.
Next Document: Antitumor carbazoles.